Decision on Eli Lilly’s Alzheimer’s drug delayed by U.S. FDA – National
The U.S. Food and Drug Administration has delayed its decision on Eli Lilly’s LLY.N experimental treatment for early Alzheimer’s disease and will hold a meeting of outside experts to discuss its safety and efficacy, the company said. The FDA’s decision came as a surprise to company officials and many Alzheimer’s experts, who had expected a … Read more
